Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 4/20 | 0.45 |
| ▸ | CCND1 | P24385 | 4/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethoxycarbonyl Group SCHEMBL27669238 | 0.80 | SLC6A2 (0.43) | SLC6A2HTR2AHTR2CCDK4CCND1 | |
| SCHEMBL6625810 | 0.79 | SLC6A2 (0.75) | SLC6A2HTR2AHTR2CCDK4CCND1 | |
| SCHEMBL6005012 | 0.78 | SLC6A2 (0.50) | SLC6A2HTR2AHTR2CCDK4CCND1 | |
| SCHEMBL6006493 | 0.78 | SLC6A2 (0.50) | SLC6A2HTR2AHTR2CCDK4CCND1 | |
| SCHEMBL4102885 | 0.77 | SLC6A2 (0.49) | SLC6A2HTR2AHTR2CNOTUM | |
| SCHEMBL10975857 | 0.77 | NOTUM (0.53) | SLC6A2HTR2AHTR2CCDK4CCND1 | |
| SCHEMBL8118593 | 0.77 | SLC6A2 (0.49) | SLC6A2HTR2AHTR2CCDK4CCND1 | |
| SCHEMBL6624835 | 0.74 | KDM4E (0.42) | SLC6A2HTR2AHTR2CBIRC5 | |
| SCHEMBL6624855 | 0.74 | SLC6A2 (0.50) | SLC6A2HTR2AHTR2CCDK4CCND1 | |
| SCHEMBL7615812 | 0.74 | SLC6A2 (1.00) | SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958850-B2 | Heteroaryl compounds for kinase inhibition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| US-20230102829-A1 | Heteroaryl Compounds For Kinase Inhibition | ARIAD PHARMACEUTICALS, INC. | 2023-03-30 | — | — | US | disclosed |
| CN-110526912-B | Heteroaryl compounds for kinase inhibition | 武田药品工业株式会社 | 2023-02-14 | — | — | CN | disclosed |
| EP-3778584-A1 | PRODUCTION PROCESS OF 2-CHLORO-4-HETEROARYL-PYRIMIDINE DERIVATIVES | ARIAD Pharmaceuticals, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778584-A1 | PRODUCTION PROCESS OF 2-CHLORO-4-HETEROARYL-PYRIMIDINE DERIVATIVES | ARIAD Pharmaceuticals, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3409669-B1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMA INC (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3409669-B1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMA INC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20190218212-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2019-07-18 | — | — | US | disclosed |
| US-20190218212-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2019-07-18 | — | — | US | disclosed |
| US-10227342-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| EP-0339887-B1 | Process for the preparation of indigo compounds | MITSUI TOATSU CHEMICALS (JP) | 1996-07-10 | — | — | EP | disclosed |
| EP-0368508-B1 | Process for the preparation of indigo compounds | MITSUI TOATSU CHEMICALS (JP) | 1994-09-14 | — | — | EP | disclosed |
| US-5187283-A | Reacting indole(or derivatives) with organic hydroperoxide in presence of group 4,5 or 6 metals and removing water during reaction | MITSUI TOATSU CHEMICALS, INC. (JP) | 1993-02-16 | — | — | US | disclosed |
| EP-0487322-A1 | Process for the preparation of indigo compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-05-27 | — | — | EP | disclosed |
| US-5112987-A | Process for the preparation of indigo compounds | MITSUI TOATSU CHEMICALS, INC. (JP) | 1992-05-12 | — | — | US | disclosed |
| US-4973706-A | OXIDATION OF INDOLE WITH HYDROPEROXIDE | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1990-11-27 | — | — | US | disclosed |
| CN-1042553-A | The preparation method of indigo compound | MITSUI TOATSU CHEMICALS (JP) | 1990-05-30 | — | — | CN | disclosed |
| EP-0368508-A2 | Process for the preparation of indigo compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-05-16 | — | — | EP | disclosed |
| CN-1037527-A | The preparation method of indigo compound | MITSUI TOATSU CHEMICALS (JP) | 1989-11-29 | — | — | CN | disclosed |
| EP-0339887-A1 | Process for the preparation of indigo compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218212-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | SLC6A2 4839/4885HTR2A 1220/4885HTR2C 735/4885 |
| US-11958850-B2 | Heteroaryl compounds for kinase inhibition | ERBB2, EGFR, ERBB3 | SLC6A2 4839/4885HTR2A 1220/4885HTR2C 735/4885 |
| US-10227342-B2 | Heteroaryl compounds for kinase inhibition | ERBB2, EGFR, ERBB3 | SLC6A2 4839/4885HTR2A 1220/4885HTR2C 735/4885 |
| US-20230102829-A1 | Heteroaryl Compounds For Kinase Inhibition | ERBB2, EGFR, ERBB3 | SLC6A2 4839/4885HTR2A 1220/4885HTR2C 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.